Truemeds in talks to acquire DealShare at 95% ниже peak valuation

Deal structure and valuation

According to Inc42, the acquisition would value DealShare at slightly over $90 million, representing a 95% decline from its 2022 peak valuation of $1.7 billion. The transaction would involve a share-swap, with Truemeds issuing shares to DealShare’s investors at a reported valuation of around $600 million.

The terms of the deal and the future operational structure of DealShare are still being finalised, as per the report.

DealShare’s valuation decline

Inc42 reports that DealShare’s valuation drop follows a business contraction and the departure of its entire founding team. The company was last valued at $1.7 billion in 2022, during a period of heightened investor interest in ecommerce startups.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

This potential acquisition highlights the volatility of startup valuations, particularly for companies that raised capital at frothy multiples during peak market conditions. For founders, it underscores the importance of sustainable growth over rapid scaling, as well as the risks of leadership instability. For investors, it serves as a reminder of how quickly market sentiment can shift, especially when a startup’s core business model faces challenges.

Key takeaways

• This acquisition, if completed, would signal the challenges faced by ecommerce startups that raised at high valuations during peak funding periods.
• Founders and investors may see this as a case study in how quickly valuations can correct when growth stalls and leadership changes.
• The share-swap structure could become a template for other distressed startups seeking exits without immediate cash payouts.